CVS Health falls 12.5% after quarterly results and split announcement

What happened

CVS Health (CVS) fell 12.5% on November 4, 2026, after quarterly results beat estimates and management said it would split the company into two public firms. The company reported earnings per share of $2.09 against $1.65 expected, 26.7% above estimates, and said it would separate its retail pharmacy and community healthcare business from its health-insurance and pharmacy-benefit operations by the first half of 2028. CNBC and Barrons reported the planned split, while Seeking Alpha and Zacks Investment Research covered the quarterly beat and the company’s raised outlook.

How big was the move

The decline was large relative to CVS Health’s typical trading: the stock’s move was 5.3 times a typical daily move and trading volume was 3.9 times its 20-day average. The stock fell 11.1% over the last five sessions while the S&P 500 rose 1.6% on the day, leaving the stock 15.8 percentage points worse than the healthcare sector median, which rose 3.3%. The company’s market value on the session was $115.43 billion.

Investors appeared to weigh the split announcement more heavily than the beat. Earnings were the direct cause of the move for the session, but the strategic review and plan to reverse the vertical integration from the Aetna acquisition introduced an added layer of uncertainty. That combination, together with unusually heavy trading, pushed the market reaction well beyond a routine earnings repricing.

The technical picture

The stock closed 11.5% below its 20-day moving average, 12.0% below its 50-day moving average and 10.0% below its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, even as the share price has weakened. The Relative Strength Index (14 days) stood at 30, within a neutral range between 30 and 70.

Shorter-term performance showed a meaningful pullback: the stock fell 7.5% over one month and 16.9% over three months, while it rose 1.9% over one year and was 10.3 percentage points behind the S&P 500 over that period. The stock was 27.8% below its 52-week high and 60-day volatility was 37% annualized, a level higher than 81% of its own readings over five years. Together, those indicators suggest higher-than-normal uncertainty among traders even as the longer-run trend remains intact.

Fundamentals and valuation

For the four quarters through September 30, 2026, CVS Health reported revenue of $420.61 billion, which grew 6.7% from a year earlier. Diluted earnings per share for that period were $8.59, which rose 2160.5% from a year earlier. Gross margin improved to 14.2% from 13.9% a year earlier, and operating margin widened to 3.6% from 1.2%. Free-cash-flow margin stood at 3.7% and return on invested capital was 4.1%. The balance sheet showed net debt of 3.2 times EBITDA, and share count increased by 1.7% over one year.

On valuation metrics, the stock traded at 9.3 times trailing earnings, the lowest reading of the past five years (five-year median: 17.3 times earnings). Price to forward earnings was 9.9 times expected earnings and free-cash-flow yield was 13.5%. PromtFinance scores ranked the company 99 for Value (Exceptional), 78 for Growth (Positive), 50 for Quality (Neutral), 40 for Momentum (Weak), 91 for Revisions (Exceptional) and 78 for Stability (Positive). Those scores underscore a disparity: the shares appeared attractively valued on traditional metrics even as momentum and market sentiment weakened.

Earnings and analyst expectations

CVS Health last reported on November 4, 2026, with quarterly earnings per share of $2.09 versus the Zacks Consensus Estimate of $1.62 and prior-year EPS of $1.60. The company has posted eight consecutive quarters beating estimates and the average surprise over the last four reports was 23.3% above estimates. Management raised its full-year 2026 outlook, citing gains in health-care benefits and pharmacy segments, and the typical two-day reaction after recent reports was to rise 0.8%.

Analysts covering the stock numbered 41, with 85% rating the stock Buy or Strong Buy and the consensus rating listed as Buy. The consensus price target was $111.25, 39.1% above the closing price on November 4, 2026. That gap between target and current market price highlights why some investors may view the pullback as a buying opportunity, while others remain cautious about the operational implications of a split.

What to watch

• Next scheduled earnings report on February 9, 2027.
• The company’s timetable to split into two public companies by the first half of 2028, separating retail pharmacy and community healthcare from health-insurance and pharmacy-benefit operations; announced by CVS Health and reported by CNBC and Barrons.
• How management’s raised full-year 2026 outlook and the quarterly beat interact with investor response to the split, noting the company’s eight consecutive quarters beating estimates and an average surprise of 23.3% over the last four reports.
• Valuation metrics and shareholder structure: 9.3 times trailing earnings, the lowest reading of the past five years, and net debt of 3.2 times EBITDA.